NCCN Guidelines recommend brentuximab vedotin plus CHP as a preferred first-line therapy option for ALCL (category 1) or other CD30-positive entities including PTCL-NOS (category 2A). The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.